Toward precision medicine of breast cancer

Theoretical Biology and Medical Modelling

Volumn 13, Issue 1, 2016, Pages

  Carels, Nicolas ^a   Spinassé, Lizânia Borges ^a   Tilli, Tatiana Martins ^a   Tuszynski, Jack Adam ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Hallmarks; Omics; Pharmacogenetics; Profiling; Signaling networks; Stem cell; Therapy; Tumor heterogeneity

Indexed keywords

DNA; HORMONE; PROTEOME; TRANSCRIPTOME;

BIOLOGICAL MODEL; BIOLOGY; BREAST; BREAST NEOPLASMS; CELL PROLIFERATION; CYTOLOGY; FEMALE; GENE REGULATORY NETWORK; GENETICS; HUMAN; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; STEM CELL;

BREAST; BREAST NEOPLASMS; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DNA; FEMALE; GENE REGULATORY NETWORKS; HORMONES; HUMANS; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MODELS, BIOLOGICAL; PHARMACOGENETICS; PRECISION MEDICINE; PROTEIN INTERACTION MAPPING; PROTEOME; SIGNAL TRANSDUCTION; STEM CELLS; TRANSCRIPTOME;

EID: 84978655449     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/s12976-016-0035-4     Document Type: Review

References (210)

1. Cecilio AP, Takakura ET, Jumes JJ, Dos Santos JW, Herrera AC, Victorino VJ, et al. Breast cancer in Brazil: epidemiology and treatment challenges. Breast Cancer. 2015;7:43-9. doi: 10.2147/BCTT.S50361.
2. Rahman M, Hasan MR. Cancer metabolism and drug resistance. Metabolites. 2015;5(4):571-600. doi: 10.3390/metabo5040571.
3. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, et al. Precision medicine for metastatic breast cancer - limitations and solutions. Nat Rev Clin Oncol. 2015;12(12):693-704. doi: 10.1038/nrclinonc.2015.123.
4. Lu YF, Goldstein DB, Angrist M, Cavalleri G. Personalized medicine and human genetic diversity. Cold Spring Harb Perspect Med. 2014;4(9):a008581.
5. Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard J-Y, Eggermont A, et al. Delivering precision medicine in oncology today and in future - the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25:1673-8. doi: 10.1093/annonc/mdu217.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
7. Wahle KW, Brown I, Rotondo D, Heys SD. Plant phenolics in the prevention and treatment of cancer. Adv Exp Med Biol. 2010;698:36-51.
8. Liu RH. Potential synergism of phytochemicals in cancer prevention: mechanisms of action. J Nutr. 2004;134:3479S-85S.
9. Fresco P, Borges F, Diniz C, Marques MP. New insights into the anticancer properties of polyphenols. Med Res Rev. 2006;26:747-66.
10. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71:1397-421.
11. Pelekanou V, Leclercq G. Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis. Int J Dev Biol. 2011;55:869-78. doi: 10.1387/ijdb.113369vp.
12. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia. 2000;5:227-41.
13. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15:1010-2.
14. Travers MT, Barber MC, Tonner E, Quarrie L, Wilde CJ, Flint DJ. The role of prolactin and growth hormone in the regulation of casein gene expression and mammary cell survival: relationships to milk synthesis and secretion. Endocrinology. 1996;137:1530-9.
15. Brisken C, Rajaram RD. Alveolar and lactogenic differentiation. J Mammary Gland Biol Neoplasia. 2006;11:239-48.
16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
17. Su Y, Subedee A, Bloushtain-Qimron N, Savova V, Krzystanek M, Li L, et al. Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer. Cell Reports. 2015;11:1549-63.
18. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32:2142-50.
19. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67.
20. Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, et al. Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One. 2013;8(10):e77281. doi: 10.1371/journal.pone.0077281.
21. Weissenstein U, Schumann A, Reif M, Link S, Toffol-Schmidt UD, Heusser P. Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer. 2012;12:206.
22. Mannello F. Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Med. 2013;11:169.
23. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253-70.
24. low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer. 2013;13:289.
25. Kosaka PM, Pini V, Ruz JJ, da Silva RA, González MU, Ramos D, et al. Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor. Nat Nanotechnol. 2014;9(12):1047-53.
26. Liang L, Deng L, Chen Y, Li GC, Shao C, Tischfield JA. Modulation of DNA end joining by nuclear proteins. J Biol Chem. 2005;280(36):31442-9.
27. Hornsby C, Page KM, Tomlinson IP. What can we learn from the population incidence of cancer? Armitage Doll revisited Lancet Oncol. 2007;8:1030-8.
28. Jiang Y, Pjesivac-Grbovic J, Cantrell C, Freyer JP. A multiscale model for avascular tumor growth. Biophys J. 2005;89:3884-94.
29. Menchon SA, Condat CA. Cancer growth: predictions of a realistic model. Phys Rev E Stat Nonlin Soft Matter Phys. 2008;78:022901.
30. Wallace DI, Guo X. Properties of tumor spheroid growth exhibited by simple mathematical models. Frontiers Oncol. 2013. doi: 10.3389/fonc.2013.00051.
31. Frieboes HB, Zheng X, Sun C-H, Tromberg B, Gatenby R, Cristini V. An integrated computational/experimental model of tumor invasion. Cancer Res. 2006;66:1597-604.
32. Stamper IJ, Byrne HM, Owen MR, Maini PK. Modelling the role of angiogenesis and vasculogenesis in solid tumour growth. Bull Math Biol. 2007;69:2737-72.
33. Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol. 2008;3:221-47. doi: 10.1146/annurev.pathmechdis.3.121806.151523.
34. Friesen DE, Baracos VE, Tuszynski JA. Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia. Theor Biol Med Model. 2015;12:17. doi: 10.1186/s12976-015-0015-0.
35. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467-72.
36. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21.
37. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970-6. doi: 10.1038/ng.2702.
38. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338-45.
39. Burrell RA, Juul N, Johnston SR, Reis-Filho JS, Szallasi Z, Swanton C. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. J Cell Biochem. 2010;111(4):782-90.
40. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155-60.
41. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012;149:994-1007.
42. Comai L. The advantages and disadvantages of being polyploid. Nat Rev Genet. 2005;6(11):836-46.
43. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264-78.
44. de Bruin EC, Taylor TB, Swanton C. Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Med. 2013;5:101.
45. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306-13.
46. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-92. doi: 10.1056/NEJMoa1113205.
47. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741-51.
48. Demidenko E. The assessment of tumour response to treatment. Appl Stat. 2006;55:365-77.
49. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374-83.
50. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144:646-74.
51. Wertz IE, Dixit VM. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ. 2010;17:14-24.
52. Sudarsanam S, Johnson DE. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel. 2010;13:31-40.
53. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177:893-903.
54. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol. 2005;171:361-71.
55. Cooper S, Shayman JA. Revisiting retinoblastoma protein phosphorylation during the mammalian cell cycle. Cell Mol Life Sci. 2001;58:580-95.
56. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8:671-82.
57. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10:51-7.
58. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31:9-18.
59. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611-22.
60. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72-6.
61. Raynaud CM, Hernandez J, Llorca FP, Nuciforo P, Mathieu MC, Commo F, et al. DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol. 2010;33:341-5.
62. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010;36:321-31.
63. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789-91.
64. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117-34.
65. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial- to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010;107:15449-54.
66. Hlubek F, Brabletz T, Budczies J, Pfeiffer S, Jung A, Kirchner T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int J Cancer. 2007;121:1941-8.
67. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649-69.
68. McGowan PM, Kirstein JM, Chambers AF. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol. 2009;5:1083-98.
69. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009;1:a003129.
70. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, et al. Identifying sitespecific metastasis genes and functions. Cold Spring Harb Symp Quant Biol. 2005;70:149-58.
71. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393-410.
72. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.
73. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:537-48.
74. Warburg O. On the origin of cancer cells. Science. 1956;123:309-14.
75. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2010;6:127-48.
76. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92:329-33.
77. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104:19345-50.
78. Teng MWL, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008;84:988-93.
79. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1-14.
80. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31:220-7.
81. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010;328:749-52.
82. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179-204.
83. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99.
84. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008;135:1161-3.
85. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 2010;141:52-67.
86. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2008;29:22-8.
87. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage- assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649-56.
88. Hanahan D, Coussens LM. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell. 2012;21:309-22.
89. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res. 2008;6:1521-33.
90. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-7.
91. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013;10(4):191-210. doi: 10.1038/nrclinonc.2013.29.
92. Daniele G, Corral J, Molife LR, de Bono JS. FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep. 2012;14(2):111-9. doi: 10.1007/s11912-012-0225-0.
93. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives. Cancer Discov. 2013;3(3):264-79.
94. Xue M, Cao X, Zhong Y, Kuang D, Liu X, Zhao Z, et al. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des. 2012;18(20):2901-13.
95. Chen HX, Sharon E. IGF-1R as an anti-cancer target - trials and tribulations. Chinese J Cancer. 2013;32(5):242-52.
96. Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci. 2013;126(8):1713-9.
97. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the Point of Inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021-31.
98. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153-83.
99. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103-19.
100. Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. de Bono JS, ed. Therapeutic Advances Med Oncol. 2011;3(1 Suppl):S7-S19. doi: 10.1177/1758834011422556.
101. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130-46.
102. Epstein EH, De Sauvage FJ, Xie J, Murone M, Luoh S-M, Ryan A, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90-2.
103. Onishi H, Katano M. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J Gastroenterol. 2014;20(9):2335-42.
104. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4(2):68-75.
105. Logan CW, Nusse R. The Wnt signaling pathway in development and disease. Cell Dev Bio. 2004;20:781-810.
106. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11-26.
107. Jain S, Santa-Maria CA, Gradishar WJ. The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer. Oncology. 2015;29(7):473-8. 481.
108. Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2009;4:CD004562. doi: 10.1002/14651858.CD004562.pub4.
109. Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targetedtherapy for breast cancer. Breast Cancer Res Treat. 2015;151(1):27-40.
110. Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015;6(3):231-9. doi: 10.4331/wjbc.v6.i3.231.
111. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209-19.
112. Zelnak AB, O'Regan RM. Optimizing endocrine therapy for breast cancer. J Natl Compr Canc Netw. 2015;13(8):e56-64.
113. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer. 2007;110:1677-86.
114. Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res. 2014;16(1):204.
115. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20:633-43.
116. Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010;596:467-88.
117. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol. 2005;78:585-94.
118. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipidanchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56:1177-92.
119. Stella B, Arpicco S, Peracchia MT, Desmaële D, Hoebeke J, Renoir M, et al. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci. 2000;89:1452-64.
120. Brigui I, Djavanbakht-Samani T, Jolles B, Pigaglio S, Laigle A. Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1. Biochem Pharmacol. 2003;65:747-54.
121. Shoji Y, Nakashima H. Current status of delivery systems to improve target efficacy of oligonucleotides. Curr Pharm Des. 2004;10:785-96.
122. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067-70.
123. Garcia-Ojalvo J, Martinez AA. Towards a statistical mechanics of cell fate decisions. Curr Opin Genetics Dev. 2012;22:619-26.
124. Ying Q-L, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, et al. The ground state of embryonic stem cell self-renewal. Nature. 2008;453:519-23.
125. Rolland T, Taşan M, Charloteaux B, Pevzner SJ, Zhong Q, Sahni N, et al. A proteome-scale map of the human interactome network. Cell. 2014;159(5):1212-26.
126. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci U S A. 2008;104(21):8685-90.
127. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet. 2009;18(2):R163-8.
128. Liu X, Wang J, Chen L. Whole-exome sequencing reveals recurrent somatic mutation networks in cancer. Cancer Lett. 2013;340(2):270-6.
129. Esteller M. Aberrant DNA, methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol. 2005;45:629-56.
130. Meaburn E, Schulz R. Next generation sequencing in epigenetics: insights and challenges. Semin Cell Dev Biol. 2012;23(2):192-9.
131. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today. 2015. doi: 10.1016/j.drudis.2015.08.005.
132. West J, Bianconi G, Severini S, Teschendorff AE. Differential network entropy reveals cancer system hallmarks. Sci Rep. 2012;2:802.
133. Carels N, Tilli T, Tuszynski JA. A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases. PLoS One. 2015;10(1):e0115054.
134. Carels N, Tilli T, Tuszynski JA. Optimization of combination chemotherapy based on the calculation of network entropy for protein-protein interactions in breast cancer cell lines. EPJ Nonlinear Biomed Physics. 2015;3:6.
135. Gabrovska PN, Smith RA, Haupt LM, Griffiths LR. Gene expression profiling in human breast cancer - toward personalised therapeutics? Open Breast Cancer J. 2010;2:46-59.
136. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol. 2007;60(12):1205-19.
137. EGAPP (Evaluation of Genomic Applications in Practice and Prevention) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med. 2009;11(1):66-73.
138. Abba MC, Lacunza E, Butti M, Aldaz CM. Breast cancer biomarker discovery in the functional genomic age: A systematic review of 42 gene expression signatures. Biomark Insights. 2010;5:103-18.
139. Islam S, Kjällquist U, Moliner A, Zajac P, Fan J-B, Lönnerberg P, et al. Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome Res. 2011;21:1160-7.
140. Cui Y, Irudayaraj J. Advanced ReviewInside single cells: quantitativeanalysis with advanced opticsand nanomaterials. WIREs Nanomed Nanobiotechnol. 2015;7(3):387-407. doi: 10.1002/wnan.1321.
141. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621-8.
142. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185-93.
143. Amemiya Y, Bacopulos S, Al-Shawarby M, Al-Tamimi D, Naser W, Ahmed A, et al. A comparative analysis of breast and ovarian cancer-related gene mutations in Canadian and Saudi Arabian patients with breast cancer. Anticancer Res. 2015;35:2601-10.
144. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
145. Wang V, Wu W. MicroRNA: A new player in breast cancer development. J Cancer Mol. 2007;3(5):133-8.
146. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A. 2006;103:9136-41.
147. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25:6188-96.
148. Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509:582-7.
149. Sharma K, D'Souza RC, Tyanova S, Schaab C, Wiśniewski JR, Cox J, et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 2014;8(5):1583-94.
150. Lawrence RT, Perez EM, Hernández D, Miller CP, Haas KM, Irie HY, et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015;11(4):630-44.
151. Eyckerman S, Verhee A, Van der Heyden J, Lemmens I, Ostade XV, Vandekerckhove J, et al. Design and application of a cytokine-receptor-based interaction trap. Nat Cell Biol. 2001;3:1114-9.
152. Dreze M, Monachello D, Lurin C, Cusick ME, Hill DE, Vidal M, et al. High-quality binary interactome mapping. Methods Enzymol. 2010;470:281-315.
153. Cusick ME, Yu H, Smolyar A, Venkatesan K, Carvunis A-R, Simonis N, et al. Literature-curated protein interaction datasets. Nat Methods. 2009;6:39-46.
154. Rietman E, Bloemendal A, Platig J, Tuszynski J, Klement GL. Gibbs free energy of protein-protein interactions reflects tumor stage. doi:10.1101/022491.
155. Banerji CR, Miranda-Saavedra D, Severini S, Widschwendter M, Enver T, Zhou JX, et al. Cellular network entropy as the energy potential in Waddington's differentiation landscape. Sci Rep. 2013;3:3039.
156. Breitkreutz D, Hlatky L, Rietman E, Tuszynski JA. Molecular signaling network complexity is correlated with cancer patient survivability. Proc Natl Acad Sci U S A. 2012;109(23):9209-12.
157. Teschendorff AE, Severini S. Increased entropy of signal transduction in the cancer metastasis phenotype. BMC Syst Biol. 2010;4:104.
158. Demetrius L, Manke T. Robustness and network evolution - an entropic principle. Physica A. 2005;346:682-96.
159. Barabási AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet. 2004;5(2):101-13.
160. Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411(6833):41-2.
161. Eisenberg E, Levanon EY. Preferential attachment in the protein network evolution. Phys Rev Lett. 2003;91:138701.
162. Milo R, Shen-Orr SS, Itzkovitz S, Kashtan N, Alon U. Network motifs: simple building blocks of complex networks. Science. 2002;298:824-7.
163. Cohen R, Havlin S. Scale-free networks are ultra small. Phys Rev Lett. 2003;90:058701.
164. Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science. 2002;296:910-3.
165. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabási A-L. Hierarchical organization of modularity in metabolic networks. Science. 2002;297:1551-5.
166. Holme P, Huss M, Jeong H. Subnetwork hierarchies of biochemical pathways. Bioinformatics. 2003;19:532-8.
167. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature. 2000;406(6794):378-82.
168. Yeger-Lotem E, Sattath S, Kashtan N, Itzkovitz S, Milo R, Pinter RY, et al. Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction. Proc Natl Acad Sci U S A. 2004;101(16):5934-9.
169. de Matos SR, Emmert-Streib F. Bagging statistical network inference from large-scale gene expression data. PLoS One. 2012;7(3):e33624.
170. Mahesh S, Mangla N, Pooja V, Bhyratae SA. Reconstruction of Gene Regulatory Network to identify prognostic molecular markers of the reactive stroma of breast and prostate cancer using information theoretic approach. Int J Innovative Res Comput Commun Eng. 2015;3(10):303-10.
171. Madhamshettiwar PB, Maetschke SR, Davis MJ, Reverter A, Ragan MA. Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets. Genome Med. 2012;4(5):41.
172. Fumiã HF, Martins ML. Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes. PLoS One. 2013;8(7):e69008.
173. Kitano H. Biological robustness. Nat Rev Genet. 2004;5(11):826-37.
174. Kitano H. Towards a theory of biological robustness. Mol Syst Biol. 2007;3:137.
175. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Sci Acad USA. 2012;109:2724.
176. Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:469251.
177. Kapoor S, Rallabandi VP, Sakode C, Padhi R, Roy PK. A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design. Theor Biol Med Model. 2013;10:68. doi: 10.1186/1742-4682-10-68.
178. Lehár J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007;3:80.
179. Koizumi Y, Iwami S. Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs. Theor Biol Med Model. 2014;11:41. doi: 10.1186/1742-4682-11-41.
180. Yurkiewicz S. The prospects for personalized medicine. Hastings Cent Rep. 2010;40:14-6.
181. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist. 1999;4(5):426-7.
182. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;21:14-55.
183. Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16(6):S4-9.
184. Burke W, Brown Trinidad S, Press NA. Essential elements of personalized medicine. Urol Oncol. 2014;32(2):193-7.
185. McGowan ML, Settersten Jr RA, Juengst ET, Fishman JR. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine. Urol Oncol. 2014;32(2):187-92.
186. Tavassoli FA, Millis RR, Boecker W, Lakhani SR. Lobular Neoplasia. In: Tavassoli FA, Devilee P, et al., editors. World Health Organization classification of tumours. Lyon, France: IARC Press; 2003. p. 60-2.
187. Almendro V, Fuster G. Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol. 2011;13(11):767-73.
188. Karczewski KJ, Daneshjou R, Altman RB. Chapter 7: Pharmacogenomics. PLoS Comput Biol. 2012;8(12):e1002817.
189. Jain KK. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother. 2005;6(9):1463-76.
190. Workman P. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr Cancer Drug Targets. 2001;1(1):33-47.
191. Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother Pharmacol. 2003;52(1):S45-56.
192. André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics. 2013;14(8):931-9.
193. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4(6):285-99.
194. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487-91.
195. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496-526.
196. EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
197. de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen. Clin Pharmacokinet. 2015;54(8):797-810.
198. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062-75.
199. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85(2):151-9.
200. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55(5):471-8.
201. Phan M, Venitz J. Summary minutes of the Advisory Committee Pharmaceutical Science Clinical Pharmacology Subcommittee 18-19 Oct 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4248m1.pdf. Accessed 12 Out 2015.
202. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011;90(4):605-11.
203. Damia G, Garattini S. The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev. 2014;40(8):909-16.
204. Garattini L, Curto A, Freemantle N. Personalized medicine and economic evaluation in oncology: all theory and no practice? Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):733-8.
205. Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, et al. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015;7(1):20.
206. Legres LG, Janin A, Masselon C, Bertheau P. Beyond laser microdissection technology: follow the yellow brick road for cancer research. Am J Cancer Res. 2014;4(1):1-28.
207. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955-61.
208. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature. 2012;483:603-7.
209. European Commission. Use of '-omics' technologies in the development of personalised medicine. 2013; http://ec.europa.eu/health/files/latest-news/2013-10-personalised-medicine-en.pdf (10 January 2016, date last accessed).
210. Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer. 2014;111(10):1881-7.